Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Borderline Personality Disorder

Borderline Personality Disorder

Borderline Personality Disorder is a complex and multifaceted mental health condition characterized by pervasive instability in interpersonal relationships, self-image, emotions, and impulse control. This instability manifests in extreme emotional reactions, fear of abandonment, and self-destructive behaviors. The disorder significantly impacts daily functioning, often leading to distress in both personal and professional domains.
Genetic and Environmental Contributions
Borderline Personality...

Clinically Relevant Drug Product Specifications: Methods of Establishment

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The evolving process of European combination product review, Part II.

Medical device technology·2009

Same author

The evolving process of European combination product review, Part I.

Medical device technology·2008

Same author

Who owns the 510(k)?

Medical device technology·2008

Same author

FDA draft guidance on computerised systems used in clinical trials.

Medical device technology·2005

Same author

The essential element of ethics.

Medical device technology·2004

Same author

Guidance on submitting quality system information.

Medical device technology·2004

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

New European guidance on borderline products.

Maria E Donawa¹,

¹Donawa Lifescience Counsulting, Piazza Albania 10, I-00156 Rome, Italy. medonawa@donawa.com

Medical Device Technology

|October 27, 2009

Summary

The European Commission updated guidance on classifying medical products as either medical devices or medicinal products. A new manual with practical examples is also available to aid in this determination.

Area of Science:

Regulatory Science
Pharmaceutical Law

Background:

The European Commission has revised its guidance on distinguishing between medical devices and medicinal products.
This update is crucial for manufacturers navigating complex regulatory landscapes.

Purpose of the Study:

To summarize the European Commission's updated guidance on medical product classification.
To highlight the newly issued manual providing practical examples for regulatory determination.
To inform stakeholders about recent changes in medical device and medicinal product regulations.

Main Methods:

Review of the European Commission's updated guidance document.
Analysis of the content and examples within the new practical manual.
Discussion of the implications for product classification.

More Related Videos

Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry

Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry

Published on: November 22, 2024

Related Experiment Videos

Last Updated: Jun 19, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry

Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry

Published on: November 22, 2024

Main Results:

The European Commission has issued revised guidelines for classifying medical products.
A new manual offers practical case studies to aid in regulatory decision-making.
These documents aim to clarify the regulatory pathway for products.

Conclusions:

Stakeholders must familiarize themselves with the updated guidance and manual.
Accurate classification is essential for market access and compliance in the EU.
The updated resources aim to streamline the regulatory process for medical products.